Apex Biotechnology Corp Cash Flow-to-Debt Ratio
Apex Biotechnology Corp cash flow-to-debt ratio. Apex Biotechnology Corp (1733) has a Cash Flow-to-Debt Ratio of 0.01x as of September 2025, meaning its operating cash flow of NT$5.19 Million could theoretically repay 0% of its total liabilities (NT$494.69 Million) in one year. Check 1733 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Apex Biotechnology Corp (2002–2024)
Cash flow-to-debt ratio of Apex Biotechnology Corp from 2002 to 2024. Historical debt coverage capacity for Apex Biotechnology Corp across 23 annual periods. Check Apex Biotechnology Corp total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Apex Biotechnology Corp Cash Flow-to-Debt Ratio by Year (2002–2024)
Apex Biotechnology Corp cash flow-to-debt ratio by year from 2002 to 2024. Year-by-year debt coverage analysis for Apex Biotechnology Corp. For the full cash flow conversion analysis, see 1733 cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.55x | NT$328.67 Million | NT$595.70 Million | ▲ +19.8% |
| 2023 | 0.46x | NT$230.39 Million | NT$500.07 Million | ▲ +1106.2% |
| 2022 | 0.04x | NT$26.62 Million | NT$696.81 Million | ▼ -80.5% |
| 2021 | 0.20x | NT$179.87 Million | NT$916.91 Million | ▼ -29.7% |
| 2020 | 0.28x | NT$280.60 Million | NT$1.01 Billion | ▼ -31.4% |
| 2019 | 0.41x | NT$462.52 Million | NT$1.14 Billion | ▲ +442.7% |
| 2018 | 0.07x | NT$67.57 Million | NT$901.70 Million | ▲ +9.5% |
| 2017 | 0.07x | NT$70.83 Million | NT$1.03 Billion | ▼ -82.4% |
| 2016 | 0.39x | NT$298.06 Million | NT$768.49 Million | ▼ -37.2% |
| 2015 | 0.62x | NT$472.15 Million | NT$764.69 Million | ▲ +79.6% |
| 2014 | 0.34x | NT$267.60 Million | NT$778.52 Million | ▼ -43.0% |
| 2013 | 0.60x | NT$484.77 Million | NT$803.47 Million | ▼ -13.0% |
| 2012 | 0.69x | NT$509.67 Million | NT$735.18 Million | ▼ -1.4% |
| 2011 | 0.70x | NT$273.45 Million | NT$388.76 Million | ▼ -51.6% |
| 2010 | 1.45x | NT$465.59 Million | NT$320.60 Million | ▲ +12.6% |
| 2009 | 1.29x | NT$391.29 Million | NT$303.31 Million | ▼ -4.9% |
| 2008 | 1.36x | NT$299.96 Million | NT$221.21 Million | ▼ -23.8% |
| 2007 | 1.78x | NT$364.62 Million | NT$204.80 Million | ▼ -4.2% |
| 2006 | 1.86x | NT$363.71 Million | NT$195.73 Million | ▲ +95.7% |
| 2005 | 0.95x | NT$212.14 Million | NT$223.36 Million | ▼ -44.1% |
| 2004 | 1.70x | NT$218.54 Million | NT$128.64 Million | ▼ -31.4% |
| 2003 | 2.48x | NT$302.25 Million | NT$122.00 Million | ▲ +178.0% |
| 2002 | 0.89x | NT$79.49 Million | NT$89.21 Million | — |